
Bayer has initiated the phase 2 trial NIRVANA to evaluate elinzanetant's potential in treating sleep disturbances in menopausal women, addressing a prevalent yet unmet need in women's health.

Bayer has initiated the phase 2 trial NIRVANA to evaluate elinzanetant's potential in treating sleep disturbances in menopausal women, addressing a prevalent yet unmet need in women's health.

Elinzanetant demonstrated positive safety and efficacy data in managing menopausal vasomotor symptoms, highlighting its potential as a treatment for improving women's quality of life during menopause.

A comprehensive review reveals a minimal 0.5% risk of perinatal death in pregnancies diagnosed with vasa previa prenatally, emphasizing the importance of timely diagnosis and reduced stress for expectant families.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

The panel discusses the importance of discussing the immunizations with patients now, as well as the value of them in future seasons.